← Leaderboards
Kai He
Oncoc4, Inc.
$666,667
Attributed
$2,000,000
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2021–22$1M$750K$500K$250K$0
'21
'22
Funding mix
By agency
NIH$2,000,000 · 1
By mechanism
R44$2,000,000 · 1
Top collaborators
- Tianhong Li2 shared
- Pan Zheng2 shared
Others in their field
Other Emerging Leaders on “Adverse Event”
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Jean Macdonald · Dana-Farber Cancer Inst$26,990,229
- Michelle Lynn Sever · Rho Federal Systems Division, Inc.$26,732,375
- Barbara Halina Braffett · George Washington University$18,816,779
- Ionut Bebu · George Washington University$18,816,779
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
Research focus
Adverse EventAftercareAntibodiesAnti-Ctla4Anti-Ctla4 AntibodiesAutoimmune DiseasesBiologicalBiopsyCancer ImmunotherapeuticsCancer ImmunotherapyCancer PatientCellsClinical ResearchCohortCtla4 GeneDisease ResistanceDoseDrug KineticsEfficacy TestingEnrollmentExhibitsFeedbackFirst-In-HumanAdvanced Disease
Grant awards (2)
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy$1,000,000
R44 · FY2022 · CA
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy$1,000,000
R44 · FY2021 · CA